[Clinical studies of the effect of a phosphorylated glycoderivative in acute viral hepatitis].
Experimentation of two i.v. doses of a uridine-5-diphosphoglucose (UDPG) in 30 cases of acute viral hepatitis is reported. The therapeutic efficacy of the drug was assessed on qualitative and quantitative parameters indicative of liver distress. Statistically significant evidence was obtained of the efficacy of UDPG in acute and serious liver disease, and of the greater effectiveness of one of the two doses used. Excellent local and general tolerance was noted.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D005260:Female; D006506:Hepatitis A / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D014532:Uridine Diphosphate Glucose / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014539:Uridine Diphosphate Sugars / Q000627:therapeutic use*
D014539:Uridine Diphosphate Sugars; D014532:Uridine Diphosphate Glucose
Ricerca clinica sull'effetto di un glicoderivato fosforilato nell'epatite acuta da virus